Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
14 NC counties are under alert, including Moore, Sampson, and Hoke counties.
Program
4-year-old kidnapped at gunpoint. The car he's believed to be in, who police think he is with and where they may be headed
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dyne Therapeutics Inc
(NQ:
DYN
)
46.09
+0.83 (+1.83%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyne Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity?
August 21, 2024
Find out the significance of the
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday?
August 13, 2024
A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified expectations for Federal Reserve rate cuts, prompting speculators to...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024
August 12, 2024
DYN stock results show that Dyne Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 12, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
July 14, 2024
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...
Via
Benzinga
Chart Of The Day: Dyne Therapeutics - Deeply Discounted
July 10, 2024
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United...
Via
Talk Markets
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
June 24, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
June 13, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
June 12, 2024
Via
Benzinga
Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React
June 12, 2024
U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cut in September.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
June 04, 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via
InvestorPlace
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
May 30, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
May 28, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
May 22, 2024
Via
Benzinga
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
May 21, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
May 20, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Is Dyne Therapeutics Stock Soaring On Monday?
May 20, 2024
Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle...
Via
Benzinga
Tech Surge Boosts Nasdaq To Record Highs
May 20, 2024
The Nasdaq Composite Index is up triple digits and marking new record highs, thanks to rising tech stocks.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
May 20, 2024
Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD.
Via
Investor's Business Daily
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
May 20, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 20, 2024
Pre-market stock movers are a great way to start the trading week and we have all of the hottest news worth reading about on Monday!
Via
InvestorPlace
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
May 20, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
May 19, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024
May 02, 2024
DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 02, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
March 27, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
Via
Benzinga
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
March 25, 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.